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Abstract: In order to utilize the neuroprotective properties of polycyclic cage compounds, and explore
the NO-donating ability of nitrophenyl groups, an array of compounds was synthesized where the
different nitrophenyl groups were appended on oxa and aza-bridged cage derivatives. Biological
evaluations of the compounds were done for cytotoxicity, neuroprotective abilities, the inhibition
of N-methyl-D-aspartate (NMDA)-mediated Ca2+ influx, the inhibition of voltage-mediated Ca2+
influx, and S-nitrosylation abilities. All of the compounds showed low toxicity. With a few
exceptions, most of the compounds displayed good neuroprotection and showed inhibitory activity
for NMDA-mediated and voltage-gated calcium influx, ranging from high (>70%) to low (20–39%)
inhibition. In the S-nitrosylation assay, the compounds with the nitro moiety as the NO-donating
group exhibited low to good nitrosylation potency compared to the positive controls. From the
biological evaluation of the tested compounds, it was not possible to obtain a simple correlation
that could explain the results across all of the biological study domains. This can be ascribed to
the independent processes evaluated in the different assays, which reiterate that neuroprotection is
a result of multifactorial biochemical mechanisms and interactions. However, these results signify
the important aspects of the pentacylcoundecylamine neuroprotectants across different biological
study realms.
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1. Introduction
Many of the most devastating neurological disorders are neurodegenerative. The prevalence
of neurodegenerative disorders is increasing worldwide with the aging population [1].
Neurodegeneration is a general term for the selective and progressive loss of the structure and
function of specific populations of neurons, and is observed in disorders such as Parkinson’s disease
(PD), Alzheimer’s disease (AD), Huntington’s disease (HD), Amyotrophic lateral sclerosis (ALS or Lou
Gehrig’s disease), and glaucoma. As per the World Health Organization (WHO) report on neurological
disorders, the global burden of disease estimates and projection for neurodegenerative diseases such as
Alzheimer’s, dementia, Parkinson’s disease, and multiple sclerosis rank second after cerebrovascular
disease in terms of disability-adjusted life years [2].
Current research implicates excitotoxicity in a variety of neuropathological conditions, suggesting
that neurodegenerative diseases with distinct aetiologies may have excitotoxicity as a common pathway.
This process takes place following the over-activation of receptors for excitatory neurotransmitters
such as the N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
(AMPA) receptors. Excitotoxins such as NMDA and kainic acid, as well as high levels of glutamate,
cause excitotoxicity. The excessive activation of glutamate receptors such as the NMDA receptor leads
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to a number of damaging consequences, including the disturbance of calcium homeostasis, formation
of free radicals, activation of mitochondrial permeability transition, and secondary excitotoxicity [3].
Neurodegenerative diseases may be caused by different mechanisms, but they share a final
common pathway to neuronal injury in the form of the overstimulation of glutamate receptors,
especially of the NMDA subtype [4]. The physiological role of the NMDA receptor is related to synaptic
plasticity, which is mediated by the entry of calcium ions through the NMDA receptor-associated
channel. However, the overactivation of NMDA receptors causes an excessive calcium ion influx,
which triggers a series of cytoplasmic and nuclear processes leading to neuronal cell death. Hence,
NMDA receptor antagonists/modulators could have potential therapeutic benefits. Apart from
NMDA receptors, calcium influx through voltage-gated calcium channels (VGCCs) is also implicated
in excitotoxicity. Due to the relevance of NMDA receptors and excitotoxic processes, research to
antagonize or desensitize NMDA receptors as a therapeutic tool has been extremely dynamic [5].
There is also extensive data to show the advantage of drugs acting on VGCCs in neurodegenerative
diseases [6], thus suggesting that VGCCs could be targeted for achieving neuroprotection.
The NMDA receptor has an S-nitrosylation site as a modulatory site that is located towards
the N-terminus, and hence the extracellular region, of the receptor. NMDA receptor activity can
be modulated by S-nitrosylation, in which the transfer of the NO group to a cysteine sulfhydryl
takes place to form a RS–NO. This S-nitrosylation results in a decrease in the channel opening,
and thus the downregulation of receptor/channel activity, avoidance of excessive Ca2+ entry,
and neuroprotection [7]. This modulation of NMDA receptor activity can be utilized in the
development of neuroprotective drugs.
Polycyclic cage compounds such as amantadine, nitromemantine, and pentacycloundecane
(Figure 1) have a relatively rigid conformation that can minimize the loss of conformational
entropy on binding to a protein/receptor/substrate, and also can be used to improve and modify
the pharmacokinetic and pharmacodynamic properties of pharmaceutically important chemical
moieties [8]. Polycyclic compounds thus provide a convenient platform for further chemical
transformations as side chain attachments and can improve the lipophilicity of the drug [9].
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Various derivatives of different polycyclic cage compounds have been used for the design and
synthesis of potential drugs against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s
disease) [8–10] and infectious diseases (malaria and dengue) [11,12].
Polycyclic structures such as adamantane derivatives and memantine block excessive NMDA
receptor and VGCC activity without disturbing normal function, and have been the centre of active
research in the field of neuroprotection for many years [8,13,14]. Following a similar therapeutic
strategy, current research used polycyclic structures to inhibit excitotoxicity and provide a molecular
platform to carry nitric oxide-donating moieties across the blood–brain barrier.
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The strategy here was thus to synthesize compounds where NO-donating moieties are linked
to polycyclic cage compounds with the hypothesis that the polycyclic cage structures bearing
NO-donating groups can act in a synergistic way to yield potential neuroprotective candidates when the
neuroprotective properties of polycyclic cage scaffolds and S-nitrosylation properties of NO-donating
groups are combined.
The general structure for the series of compounds synthesized is presented in Figure 2.
The structure of all of the compounds in this series can be divided into three parts as A, B, and C.
Part ‘A’ represents the polycyclic scaffold with a nitrogen present either as a 2◦ or 3◦ amine, to which
a carbon spacer length of 1C to 3C is attached, as represented by part ‘B’. Part ‘C’ embodies the
NO-donating moiety, which is a phenyl group with a nitro group attached at the ortho, meta, or para
position. Among the polycyclic scaffolds, oxa and aza-pentacycloundecane derivatives were selected
for synthesizing the compounds.
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Figure 2. Pictorial representation of the general structure of synthesized compounds.
A series of compounds was proposed with various structural combinations of parts A, B, and C
in order to investigate structure–activity relationships and the different structural aspects in these
molecules, and develop more insights into the neuroprotective activity thereof. In addition to the
proposed compounds, their analogues without the nitro group were also synthesized in order to
establish the effect of the nitro group on biological activities.
A series of different assays were performed on the synthesized compounds to establish biological
activity. All of the compounds were first tested for cytotoxicity. The cytotoxicity profile of these
compounds gave an optimum concentration range for a general anti-apoptotic assay to assess the
neuroprotective behavior of these compounds. Two more assays were performed in order to evaluate
the effect of the synthesized compounds on calcium influx in voltage-gated calcium channels and via
the NMDA receptor channel. Compounds were also evaluated for their S-nitrosylation ability.
2. Results and Discussion
2.1. Synthesis
Pentacyclo[5.4.0.02,6.03,1 .05,9]undecane-8-11-dione was synthesized by an earlier reported
method [15]. Compounds 4–11 were synthesized by using carboxyl activational chemistry to
conjugate the amino alcohol derivatives of oxa-pentacycloundecane with nitrobenzoic acids (Scheme 1).
The strategy for the synthesis of the amino alcohol derivatives involved reductive amination, where
pentacycloundecane dione 1 reacts with amino alcohols such as 2-aminoethanol and 3-aminopropanol
followed by reduction with sodium borohydride, which yielded the oxa-bridged pentacycloundecane
derivatives 2 and 3 via transannular cyclization. Compounds 14–18 were synthesized by nucleophilic
substitution (SN2) of the monoamine cage 13 by appropriate benzyl or phenethyl bromide.
The monoamine cage 13 was synthesized by debenzylation of 12 (NGP1-01) under high-pressure
catalytic hydrogenation. Compound 12 (NGP1-01) was synthesized by modification of an earlier
reported method [16].
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The synthetic approach for compound 20 (Scheme 2), which is an aza analogue and structural
isomer of 12, was adapted from an earlier reported method [17], with a few variations in reaction
conditions. In this approach, the monoprotection of Cookson’s cage compound was first achieved by
making a mono ketal cage derivative 19 following the reported procedure [18]. The condensation of
this mono ketal cage compound 19 with benzyl amine gave the imine. The reduction of this imine with
NaBH4, followed by acid hydrolysis, gave the desired aza-bridged compound 20. The aza compound
22 was synthesized by nucleophilic substitution (SN2) of the intermediate carbinolamine 21 with
p-nitrobenzyl bromide, using similar reaction conditions as used for compounds 14–18. Compound 21
was synthesized by debenzylation of 20 using catalytic hydrogenolysis. Compound 23, the 5-cyano
substituted analogue of compound 20, was prepared by a modification to the procedure described in
the Fourie and Snyckers patent [19].
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(206 kPa), 50 ◦C; (d) 3, CH3CN, TBAHSO4, 70 ◦C; (e) K2CO3, CH3CN, TBAHSO4, MW, 250 W,
150 ◦C, 200 Psi, 3 h.
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All of the compounds were characterized by 1H-, 13C-NMR, IR spectra and melting points.
The structure of the pentacycloundecane cage moiety was one common feature in all of the structures
of the synthesized compounds. This structural component had characteristic 1H-NMR signal patterns,
which were used unequivocally to establish the presence of the cage component in the final structures.
The most characteristic signal for the presence of a cage is the clear AB quartet, because of two
unsymmetrical protons on the C-4 bridgehead. This signal appeared at a chemical shift in the range of
δ 1.70–1.73 ppm, with a coupling constant generally in the range of 10.6–10.8 Hz.
A typical signal for the presence of an oxa-cage moiety is a triplet at a chemical shift in the range
of δ 4.61–4.75 ppm with a coupling constant in the range of 5.0–5.6 Hz. This triplet corresponded to
the single proton at the C-11 carbon, and its multiplicity was attributed to the presence of two protons
at the adjacent carbons atoms C-1 and C-10. The downfield shift of this methine hydrogen on the
C-11 carbon resulted from the deshielding effect of the adjacent oxygen atom. In the case of aza-cage
derivatives, this triplet is at a chemical shift in the range of δ 3.21–3.75 ppm, with coupling constants in
the range of 4.8–5.0 MHz. This upfield shift, compared with that of its oxa analogues, is attributed to
the electronegativity difference between nitrogen and oxygen, and thus, a reduced deshielding effect
compared to the oxa derivatives. The same trend was followed by the AB quartet of the protons of
the C-4 carbon, although it was less noticeable. The chemical shifts for the rest of the protons in the
cage component generally ranged between δ 3.00–2.00 ppm. These signals might appear simply as
multiplets or groups of multiplets, apparent quartets, and apparent triplets, depending upon the other
structural features in the molecule and the spectrometer frequency of the NMR instrument.
In 13C-NMR, in addition to the other aliphatic carbon signals of the cage compound, C-8 and
C-11 had distinct chemical shifts. The chemical shift of the C-8 carbon ranged from δ 110 to δ 95 ppm,
whereas that of C-11 corresponded to δ 82 ppm. Similar to the proton spectra, the signals in the 13C
spectra of the aza-cage derivatives also showed the similar upfield shift in comparison to their oxa
counterparts, although the difference was more noticeable for the C-8 and C-11 carbons.
In addition to the above-mentioned distinctive NMR signals, the IR spectrum of cage-containing
compounds also had a typical IR absorption for sp3 hybridised C–H. The absorption for a C–H
stretching vibration showed two characteristic peaks at ≈2950 cm−1 and ≈2850 cm−1, whereas the
absorption because of the bending mode of C–H vibration displayed two peaks at ≈1450 cm−1 and
≈1350 cm−1. The intensity of the two stretching absorptions was always strong, whereas the bending
absorption intensity was variable. Generally, the compounds comprising the cage moiety showed
a medium intensity for absorptions at ≈1450 cm−1; on the other hand, absorptions at ≈1350 cm−1 had
strong intensity. The above values varied by a few units for different cage-containing compounds,
because of the variations in the molecular structure.
After conjugation with the benzoic acid derivatives, the IR spectra of the final compounds also
showed an intense absorption peak in the region of 1750–1700 cm−1, because of the ester C=O.
The broad absorption peak of the OH functional group, which was present in the intermediates,
was absent in the conjugated oxa-bridged compounds, as the hydroxyl group had reacted with the
carboxylic group to form a new ester linkage. The typical C–H stretching and bending absorptions of
the cage structure were retained in the IR spectra of the conjugated compounds. These spectroscopic
results corroborated the structures of the final compounds.
Another interesting feature was noted when comparing the methylene –NH-CH2− peaks in
the 1H-NMR of intermediate 3 and its conjugated compounds 7–10. In intermediate 3, the –CH2−
attached to –NH appears as a triplet of doublets with J = 6.15, 1.3 Hz. Once conjugated to the benzoic
acid derivatives, this –CH2− peak is shifted downfield, because of the reasons discussed above, but
close observation of this peak (after zooming in) shows this triplet of doublets flanked by two small
doublets, thus making it an apparent quintet of doublets. This trend is universally observed in the
NMR spectra of all of the conjugated compounds (7–10). It is proposed that the conjugation leads to
a fixed conformational feature in the geometry of these molecules, so that the –CH2− group attached to
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the ester functional group comes in close proximity to the –NH-CH2− group, leading to the long-range
coupling. More investigations are needed to confirm this.
In the 1H spectrum of compound 9, the para substituted aromatic protons showed two doublets
at δ 8.27 and 8.20 ppm with J = 8.8 Hz, thus indicating a strong coupling from their respective ortho
protons (Figure 3a). On detailed observation of the aromatic region, these two doublets appeared as
a doublet of triplets, with J = 2 Hz for each triplet (Figure 3b), which substantiates the long-range
coupling of each of the aromatic protons by their respective meta and para protons, apart from strong
coupling from their ortho protons.Molecules 2018, 23, x  6 of 26 
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2.2. Biological Studies
The synthesized compounds were evaluated for their cytotoxicity, neuroprotection, the inhibition
of Ca2+ influx in ligand-mediated NMDA channels, the inhibition of Ca2+ influx in voltage-gated
channels, and S-nitrosylation ability. This was achieved by different in vitro tests where the
PC12 cell line was used for cytotoxicity and neuroprotection studies, and Ca2+ studies were
performed on synaptoneurosomes. Cytotoxicity assays were performed to assess the toxicity
Molecules 2018, 23, 308 7 of 27
profile of the compounds, and select the optimum concentration range for neuroprotection studies.
Neuroprotective studies were done to investigate the anti-apoptotic behavior of the synthesized
compounds against neurotoxin-treated PC12 cell lines. Calcium influx studies were conducted to
study the inhibitory activity of the synthesized compounds towards voltage-gated calcium channel
(VGCC) and N-Methyl-D-aspartate receptor (NMDAR)-mediated calcium influx, which is a crucial
event in the aetiology of all neurodegenerative diseases. A modified biotin-switch technique (BST)
was used to assess the S-nitrosylation ability of the compounds with NO-donating moieties.
2.2.1. Cytotoxicity Studies
The MTT proliferation assay [20] was used to assess the cytotoxicity profile of the synthesized
compounds. The PC12 cell line [21] from rat adrenal pheochromocytoma was used for the cytotoxicity
studies. The cytotoxicity profiles of the compounds were reported in terms of the percentage viability
of PC12 cells when treated with respective compounds in a concentration ranging from 1.5625 µM to
200 µM. All of the synthesized compounds showed very good toxicity profiles.
All of the compounds had CC50 values (cytotoxic concentration of the compounds to cause death
to 50% of the viable cells) of more than 200 µM. Some of the compounds showed more than 100% cell
viability (Table 1); this might be because those compounds, on treatment of the cells, increased the
activity of the succinate dehydrogenase enzyme within the mitochondria without affecting the cell
viability. Some of these compounds might be preventing baseline apoptosis. Another reason can be
the natural variations in the cellular metabolism.
Table 1. Cytotoxicity profile of the test compounds as % viability from MTT assay.
Code
% Viability at Different Concentrations
200 µM 100 µM 50 µM 25 µM 12.5 µM 6.25 µM 3.13 µM 1.56 µM
4 84.55 97.24 93.68 95.46 96.02 98.67 98.85 95.85
5 85.90 91.47 84.30 92.58 100.18 90.40 95.10 98.68
6 75.47 98.77 98.27 103.91 99.17 97.12 94.12 106.21
7 102.42 105.10 109.14 116.15 110.57 117.52 106.64 110.51
8 96.43 108.25 111.05 112.36 109.39 114.19 111.45 116.13
9 121.08 122.17 113.29 111.37 109.14 113.08 113.76 115.58
10 117.90 120.65 117.10 112.69 116.29 111.34 116.34 117.53
11 98.53 101.52 97.62 104.37 101.06 104.19 103.87 101.56
12 90.55 103.71 100.13 109.19 98.65 86.40 92.88 99.39
14 68.33 108.98 90.37 98.13 100.56 96.09 109.83 104.97
15 79.46 93.89 109.08 115.43 102.87 105.63 101.42 107.42
16 81.07 85.38 93.21 100.70 96.06 106.68 107.63 109.98
17 61.16 102.19 102.91 107.85 97.14 103.35 102.25 110.06
18 96.82 94.19 92.45 105.69 94.99 90.97 95.88 102.41
20 63.05 80.70 88.05 90.08 90.57 93.91 90.68 99.67
22 72.98 112.89 130.70 128.28 118.47 94.80 105.84 115.89
23 127.86 126.76 128.73 123.01 132.12 102.78 110.27 99.59
The introduction of a nitro group did not affect the cytotoxicity profiles of the molecules
significantly. It was also observed that the position of substitution of the nitro on the phenyl group did
not play any significant role towards the cytotoxicity of the compounds.
The highest concentration where the compounds did not show any cytotoxicity was
50 µM; therefore, this concentration was selected as the maximum concentration for the
neuroprotection studies.
2.2.2. Neuroprotection Studies
In the neuroprotection assay, the cells were stressed by paraquat (1,1-dimethyl-4,4-bipyrimidyl
chloride) as a toxin to model neurodegeneration. A dose-dependent cytotoxicity response of paraquat
towards PC12 cells was established to determine a suitable concentration and incubation time to model
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neuroprotection. At a concentration of 250 µM and a treatment period of 24 h, paraquat induced
approximately 30% cell death, while pre-treatment with N-acetyl-cysteine (NAC) (500 µM) restored
the cell viability to 85%. Cell viability was determined using the CellTiter-Blue reagent (Promega).
The neuroprotective potential of the test compounds was determined at three concentrations, i.e.,
5 µM, 25 µM, and 50 µM, by treating PC12 cells with the neurotoxin paraquat at a concentration of 250
µM. NAC was used as a positive control for each experiment to ensure that cell death was induced at
a level that is at least partially restorable.
Most of the compounds showed very good neuroprotection when compared with NAC. It is
to be noted that in all of the tests conducted to study neuroprotection, the concentration of the
positive control NAC was 500 µM, whereas the maximum concentration used for the test compounds
was 50 µM. The NAC functions as a precursor for glutathione (GSH) synthesis, and thus protects
against oxidative stress as an antioxidant [22]; as such, it may become rapidly exhausted through
paraquat-induced oxidative stress. Consequently, there is a need for a continuous supply to provide
sufficient protection. The relatively high concentrations of NAC required to afford neuroprotection
may also relate to the enzymatic process that is necessary for the biosynthesis of GSH. Excessive
concentrations of extracellular NAC shifts the equilibrium, for both its transport into the cell as well
as the enzymatic pathway required for the synthesis of GSH. These features together necessitate
a relatively high concentration of NAC to be used in order to provide significant protection. Unless
the mechanism of action of the test compounds is assumed to be similar to that of NAC, it is not
possible to make a direct comparison in terms of efficacy. In this assay, most of the test compounds
showed dose-dependent neuroprotection behavior, although some of the compounds had a negative
percentage of neuroprotection at one of the concentrations tested.
The comparison of neuroprotection results of the compounds without any nitro group (11, 10,
12, and 20) with those of their analogues with a nitro group (6, 9, 16, and 22, respectively) shows that
compounds with the nitro functional group have more neuroprotective ability against the neurotoxin
used (Table 2). The two compounds (10 and 9) that have a three-carbon linker between the amine and
ester groups were the exception. However, the difference in the neuroprotection caused by compounds
10 and 9 was statistically non-significant.
Table 2. Percentage of the neuroprotection results of the test compounds at three different concentrations.
Code %Neuroprotection 5 µM %Neuroprotection 25 µM %Neuroprotection 50 µM
4 −8.94 21.08 28.17 *
5 −13.47 24.48 −23.05
6 6.15 −0.66 26.55 *
7 14.53 5.98 −1.59
8 −10.90 9.95 39.62 *
9 −9.58 −7.78 3.42
10 −12.54 −3.92 9.52
11 14.25 9.37 1.38
12 2.88 19.88 * 3.38
14 8.04 21.55 24.87
15 4.40 4.68 11.21
16 6.02 9.68 * 18.71 **
17 5.95 5.72 16.69
18 12.72 5.52 −8.01
20 −1.58 −15.46 0.29
22 −5.36 −6.19 24.92 *
23 6.40 17.49* 15.33 *
The asterisks indicate the statistical significance (*, p < 0.05 and **, p < 0.005).
At a 50-µM concentration of the test compounds, compound 11 showed 1.38% neuroprotection,
whereas its analogous structure with the nitro functional group (6) had 26.55% neuroprotection.
Similarly, compound 12 showed 3.38% neuroprotection, and its nitro analogue (16) showed 18.71%
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neuroprotection. These results suggest that the presence of a NO-donating moiety in the structure
of the molecule enhances its neuroprotective ability, but simultaneously, the other features of the
molecule also contribute towards its neuroprotection profile. The analysis of the neuroprotection of
different positional isomers also suggested that the position of the nitro functional group on the phenyl
ring of the molecule does not influence its neuroprotective ability.
In the neurotoxicity model used in these tests, paraquat, an inducer of oxidative stress, was used as
the neurotoxin. It is possible that not all of the neuroprotective compounds would necessarily be able to
counteract the effects of paraquat, due to their specific mechanisms of action. Interestingly, compound
12 (NGP1-01), which shows neuroprotective properties through NMDA and L-type voltage-operated
calcium channels [23,24], exhibited only 3.38% neuroprotection at 50 µM under the test conditions.
It might show a better neuroprotection against other neurotoxins with different neurotoxic mechanisms.
It is also interesting to note that compound 12 gave better and more statistically significant results
at 25 µM concentration, but not at 50 µM. Compound 5 also showed better neuroprotection at
25 µM than at 50 µM, although it was with larger standard deviation. The better neuroprotection
at a lower concentration can be because these compounds became toxic to the stressed cells at
the higher concentrations. The same can be applied to the other compounds (7, 11, and 18) that
showed the highest neuroprotection at 5 µM concentration, followed by neuroprotection at 25 µM
concentration, under given test conditions. Compounds 7, 11, and 18 showed 14.53%, 14.25% and
12.72% neuroprotection at 5 µM versus 5.98%, 9.37%, and 5.52% at 25 µM, respectively. The larger
standard deviations in some of the results can be attributed to the nature of this neuroprotection assay,
where unhealthy cells (as a result of the exposure to the neurotoxin) were used. Such biological assays
are more prone to variations, especially when attempting to reverse cell death.
2.2.3. NMDA-Mediated Ca2+ Studies
The NMDA receptor (NMDAR) activity of the test compounds was evaluated on murine
synaptoneurosomes using the fluorescent ratiometric calcium indicator, Fura-2/AM. Pure DMSO was
used as the control. MK-801 and NGP1-01 were used as positive controls. Synaptoneurosomes
consisted of the presynaptic terminal, including mitochondria and synaptic vesicles, with the
postsynaptic membrane and the postsynaptic density proteins [25]. These were obtained by
the homogenization and fractionation of the rat brain cortex. The resealed vesicles or isolated
terminals break away from the axon terminals during the homogenization of the cortical tissues.
The synaptoneurosomes retain the pre- and postsynaptic properties, which makes them useful
for the study of synaptic transmission. The molecular machinery used in neuronal signaling is
also retained in the synaptoneurosomes, which are capable of the uptake, storage, and release
of neurotransmitters [26]. Freshly isolated synaptoneurosomes were loaded with Fura-2/AM
by incubation in a calcium-free buffer, so that the membrane-permeable Fura-2/AM enters the
synaptoneurosomes. These synaptoneurosomes were then suspended in a calcium-containing
buffer. NMDARs were activated by injecting a NMDA/glycine stimulation buffer, thus leading
to NMDA-mediated calcium influx. The synaptoneurosomes exhibited the desirable physiological
function, as per their fluorescence profile, when injected with the stimulation buffer, both in the
absence of any test sample and in the presence of known NMDAR blocker MK-801 (Figure 5).
The changes in the fluorescence intensity were measured before and after the activation of NMDAR.
The effect of the test compounds on this calcium influx was measured by monitoring the changes in
the fluorescence intensities.
All of the compounds were investigated for their inhibitory effect on NMDA receptor-mediated
calcium influx at a concentration of 100 µM. The percentage of the inhibition of calcium influx obtained
after the statistical analysis of raw data is depicted in Figure 6 for all of the compounds under
investigation. MK-801 and compound 12 (NGP1-01) were used as positive controls at a concentration
of 100 µM. This concentration was selected as approximately 80% inhibition of calcium flux was
observed for the positive control MK-801, and it was shown to be an effective concentration for the
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screening of polycyclic structures in synaptoneurosomal preparations [23,27]. Pure DMSO in place of
test samples was used as the control.
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and standard deviation. The asterisks indicate the statistical significance (*, p < 0.05; **, p < 0.005;
***, p < 0.001 and ****, p < 0.0001) when compared to the zero inhibition control.
All of the tested compounds showed moderate to good inhibition of NMDA-mediated calcium
influx. The control, which had DMSO in place of a test sample solution, had 0% inhibition. The positive
controls MK-801 and com ound 12 (NGP1-01) showed 72.77% and 50.84% nhibition, respectively.
T ex mine the effect of th presence of the itro group on the NMDA-mediated calci m i flux,
a comparative study of the percentage inhibiti of the compounds without any nit group o the
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phenyl ring (compounds 11, 10, and 12) was done with their analogues with nitro groups at any of the
ortho, meta, or para positions of the phenyl group. All of the compounds with the nitrophenyl group
showed better inhibitory activity than their respective parent compounds without the nitro substitution,
although the difference in the activities of non-nitro and nitro compounds was not statistically
significant. Compound 7, which is an ortho-nitro analogue of compound 10, was an exception to the
above trend, and exhibited 49.26% inhibition, whereas compound 10 showed 62.92%. Aza-compound
22 with p-nitrophenyl also showed better inhibition (55.22%) of NMDA-mediated calcium flux than
compound 20 (24.92%), which is its analogue without any nitro group on the phenyl ring.
From the study of percentage inhibition of NMDA-mediated calcium influx of different o-, m-,
and p-nitro positional isomers, it was observed that the position of the nitro group on the phenyl group
in the test compounds also plays a role in their inhibitory activities. The inhibitory activity of the
three different sets of o-, m-, and p-nitro positional isomers (4, 5, and 6; 7, 8, and 9; and 14, 15, and
16; respectively) is shown in Figure 7. In the sets of 4, 5, and 6 and 7, 8, and 9, the order of inhibitory
activity followed by the compounds is para > meta > ortho, where the geometrical symmetry of the
p-nitro compounds could be the reason for the better inhibitory activity. In the o-, m-, and p-positional
isomer set of 14, 15, and 16, the m-nitro isomer (15) has the highest activity. It is interesting to note that
this set of compounds 14, 15, and 16 has an effective two-bond distance between the cage amine and
the nitro phenyl compared to the five and six-bond distance in the former two sets. As discussed in
Section 2.1, in the 1H spectra of these compounds (14, 15, and 16), the bridging –CH2− between the
cage and the aromatic group showed an AB quartet pattern, suggesting the diastereotopic nature of
the bridging –CH2− group, and thus the conformational rigidity of such molecules with one carbon
linker. The conformational rigidity of these compounds might thus be a more dominating factor than
the symmetry factor in leading to the para > meta > ortho rank order of the other sets of compounds (4,
5, and 6 and 7, 8, and 9).
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In comparison of the activity of oxa- and aza-pentacycloundecane derivatives, the oxa-compounds
12 and 16 showed slightly better, though not significant, NMDAR inhibitory activity (50.84% and
59.6%, respectively) than their aza counterparts 20 and 22 (24.92% and 55.22%, respectively).
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2.2.4. Voltage-Gated Ca2+ Studies
The effect of the test compounds on VGCC was evaluated on murine synaptoneurosomes with the
same methodology as that for NMDA-mediated Ca2+ studies using the fluorescent ratiometric calcium
indicator, Fura-2/AM. DMSO was used as the control, whereas nimodipine and NGP1-01 were used as
positive controls, at a concentration of 100 µM. At physiologic or resting membrane potential, VGCCs
are closed. These channels were opened by injecting the depolarization buffer (containing 140 mM of
K+), and thus allowing VGCC-mediated calcium influx into the cells, which resulted in an increase in
the fluorescent ratio in the presence of calcium. The fluorescence profile of synaptoneurosomes, when
injected with the depolarization buffer in the absence of any test sample and in the presence of known
VGCC blocker nimodipine, is displayed in Figure 8.
The fluorescence intensity was measured before and after the activation of VGCC. The effect of the
test compounds on this calcium influx was measured by monitoring the changes in the fluorescence
intensities. The screening results of the test compounds are depicted in Figure 9.
Molecules 2018, 23, x  12 of 26 
 
 
(a) 
 
(b) 
Figure 8. Fluorescence profile of synaptoneurosomes in Fura-2/AM experiments for studying the 
voltage-gated Ca2+ influx. (a) Stimulation at 11.1 s by depolarization buffer in the absence of any test 
compound; (b) Stimulation at 11.1 s by depolarization buffer in the presence of a known voltage-gated 
calcium channel (VGCC) blocker (nimodipine). 
%
 In
hi
bi
tio
n
 
Figure 9. Screening of test compounds (100 μM) for their voltage-gated calcium influx using murine 
synaptoneurosomes. Each bar represents mean percentage of inhibition and standard deviation. The 
asterisks indicate the statistical significance (*, p < 0.05; **, p < 0.005 and ****, p < 0.0001) when 
compared to the control. 
The compounds under investigation showed low to moderate voltage-gated calcium influx 
inhibition. The control, which had DMSO only in place of the test sample solution, had 0% inhibition. 
The positive controls nimodipine and compound 12 (NGP1-01) showed 74.64% and 30.71% inhibition, 
respectively, although the latter value was not statistically significant. To study the effect of the 
0.76
0.78
0.8
0.82
0.84
0.86
0.88
0.9
00
:0
0.
0
00
:0
2.
0
00
:0
4.
0
00
:0
6.
0
00
:0
8.
0
00
:1
0.
0
00
:1
2.
8
00
:1
4.
8
00
:1
6.
8
00
:1
8.
8
00
:2
0.
8
00
:2
2.
8
00
:2
4.
8
00
:2
6.
8
00
:2
8.
8
00
:3
0.
8
00
:3
2.
8
00
:3
4.
8
00
:3
6.
8
34
0/
38
0 
ra
tio
Time (s)
3.05
3.1
3.15
3.2
3.25
3.3
3.35
3.4
3.45
00
:0
0.
0
00
:0
2.
0
00
:0
4.
0
00
:0
6.
0
00
:0
8.
0
00
:1
0.
0
00
:1
2.
8
00
:1
4.
8
00
:1
6.
8
00
:1
8.
8
00
:2
0.
8
00
:2
2.
8
00
:2
4.
8
00
:2
6.
8
00
:2
8.
8
00
:3
0.
8
00
:3
2.
8
00
:3
4.
8
00
:3
6.
8
34
0/
38
0 
ra
tio
Time (s)
Figure 8. Fluorescence profile of synaptoneurosomes in Fura-2/AM experiments for studying the
volt g -gated Ca2+ influx. (a) Stimulati at 1 .1 s by depolariz tion buffer in th absenc of any test
compound; (b) Stimulation at 11.1 s by depolarization buffer in the presence of a known voltage-gated
calcium channel (VGCC) blocker (nimodipine).
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Figure 9. Screening of test compounds (100 µM) for their voltage-gated calcium influx using murine
synaptoneurosomes. Each bar represents mean percentage of inhibition and standard deviation.
The asterisks indicate the statistical significance (*, p < 0.05; **, p < 0.005 and ****, p < 0.0001) when
compared to the control.
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respectively, although the latter value was not statistically significa t. To study the effect of the presence
of the nitro group on the voltage-gated calcium influx, the percentage inhibition of 10, 11, and 12
(the compounds without any nitro group on the phenyl ring) was compared with their analogues with
a nitro group at any ortho, meta, or para position of the phenyl group.
With a few exceptions, the introduction of a nitro group enhanced the percentage inhibition of
voltage-mediated calcium influx. All of the ortho, meta, and para nitro-substituted variants of 11 had
better percentage inhibitions of calcium influx, although these values were statistically non-significant.
Another interesting inference that can be drawn from above data is that the para-nitro positional
isomer always had the highest percentage inhibition, barring the exceptional case of the set of ortho,
meta, and para-substituted variants of compound 10. This indicates the para position as the more
favorable nitro substitution position for the inhibition of voltage-mediated calcium influx among this
series of compounds.
The voltage-gated calcium activity of the oxa compounds 12 and 16 (30.71% and 47.15%) was
minimally different from their aza analogues 20 and 22 (35.69% and 43.76%), respectively.
2.2.5. S-Nitsosylation Studies
For evaluating the S-nitrosylation ability of the test compounds, the biotin switch technique (BST)
was implemented, with some experimental modifications from the original reported method [28].
The rat brain homogenate was substituted with cysteine–glycine dipeptide. The ultraviolet absorbance
of pyridine-2-thione at 343 nm, which was used to detect S-nitrosylation in the reported method,
was also employed to quantify the S-nitrosylation ability. After S-methylthiolation, ascorbate was
not added for nitrosothiol decomposition, considering the spontaneous decomposition of nitrosothiol
before the N-[6-(biotinamido)hexyl]-3′-(2′-pyridyldithio)propionamide (biotin-HPDP) addition [28,29].
The cysteine thiols were allowed to react with equimolar quantities of NO donors by mixing the
two in a 1:1 stoichiometric ratio in HEN buffer. The mixture was then incubated with methyl
methanethiosulfonate (MMTS) to block the free thiols that had been left after treatment with the
NO donor. Acetone was used to precipitate the excess MMTS. Biotin-HPDP was added to form
a S-biotinylated product from the free thiols generated by the spontaneous nitrosothiol decomposition.
The amount of the by-product, pyridine-2-thione, of this reaction was estimated by the absorbance at
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343 nm, which was directly proportional to the amount of biotin-HPDP used, and hence to the extent of
S-nitrosylation. The average ultraviolet absorbance at five-minute intervals for 15 min into the reaction
was measured, and the S-nitrosylation potency was expressed as the percentage relative to the control
of each experimental run. All of the compounds with nitro groups were used for the S-nitrosylation
study. Sodium nitroprusside (SNP) and 2-(N,N-diethylamino)-diazenolate 2-oxide sodium salt hydrate
(DEA/NONOate) were used as positive controls, whereas compound 12 (NGP1-01) was used as
a negative control.
The extent of S-nitrosylation caused by each compound is expressed as the percentage relative to
that of the control, and is depicted in Figure 10. The positive controls SNP and DEA/NONOate
showed 18.39% and 16.87% S-nitrosylation of the cysteine thiol residue of the cysteine–glycine
dipeptide. As expected, the negative control 12 (NGP1-01), which did not have any NO-donating
group, showed no S-nitrosylation (experimental value of −0.96%). The test compounds showed low to
good S-nitrosylation ability compared to the positive controls.
No significant difference in S-nitrosylayion ability was observed for the ortho, meta, and para
positional isomers. However, the linker between the cage and NO-donating moiety seemed to play
a more important role for nitrosylation ability. Compounds 16 and 15, with a one-carbon hydrocarbon
linker (two bond distance) between the cage amine and the nitro phenyl group, showed the highest
S-nitrosylation percentages of 9.77% and 7.89%, respectively. Compound 14 was an exception with the
one-carbon linker, and had a very low S-nitrosylation ability, which was probably because of the steric
hindrance in the conformationally restricted structure. The S-nitrosylation potency of compounds 4, 5,
and 6, with a two-carbon ester linkage (five-bond distance) between the cage amine and nitrophenyl,
were second highest with the values of 8.14%, 7.81% and 7.76%, respectively. The compounds
with a three-carbon ester linkage (six-bond distance) showed the lowest S-nitrosylation, with 2.42%,
2.09%, and 1.61% for compounds 9, 8, and 7, respectively. The percentage S-nitrosylation by the
compound 17, with a 2C-hydrocarbon linker, was 8.34%, whereas its one-carbon analogue 15 caused
7.89% S-nitrosylation. It can be seen that for determining the S-nitrosylating ability, the steric and
conformational factors resulting from the bond distance and the position of the nitro group on the
phenyl ring are more critical than the electronic effects generated by the presence or absence of an ester
linkage. The S-nitrosylation with the aza compound 22 was 5.40%, whereas its oxa analogue showed
a slightly higher S-nitrosylation ability (9.77%).
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The standard deviation observed in these experiments was significantly smaller than that obtained
in the assays described in previous sections. This is because of the biochemical nature of these assays,
where the test conditions are more controlled than in the biological assays.
3. Materials and Methods
3.1. Synthesis
3.1.1. General Information
Unless otherwise specified, all of the chemicals were obtained from Sigma-Aldrich or Merck. All of
the chemicals were of analytical grade, and used without further purification unless specified. To obtain
dry THF, commercially available THF was pre-dried over 3Å molecular sieves before distilling over
sodium wire and a small quantity of benzophenone. To get dry DCM, commercially available DCM
was initially dried over anhydrous calcium chloride, and then distilled. The distillate was collected
and stored in an amber glass bottle away from light over 3Å molecular sieves.
The structures of the compounds were characterized by using nuclear magnetic resonance (NMR),
Fourier transform infrared (FT-IR), and mass spectrometry (MS) techniques. In the NMR spectroscopy,
1H, 13C, and distortionless enhancement of polarization transfer (DEPT) analysis were performed for
structural elucidation. The carbon peaks in the 13C-NMR spectroscopy were further differentiated as
–CH3, CH, or CH2 carbons by DEPT-135 analysis, where CH3 and CH gave positive signals, and CH2
gave a negative signals.
NMR’s were obtained using Varian 600 MHz, Varian 400 MHz, Bruker 400 MHz, and Varian
200 MHz instruments. The chemical shifts were reported as δ values in ppm downfield from
tetramethylsilane (TMS) and deuterated residual solvent peaks as internal standards (δH, CDCl3
7.26 ppm; δC, CDCl3 77.16 ppm). The coupling constants (J) are given in hertz (Hz), and the
multiplicities of NMR signals are expressed as: s, singlet; brs, broad singlet; d, doublet; t, triplet;
q, quartet; quin, quintet; m, multiplet; ABq, AB quartet; dd, doublet of doublets; td, triplet of doublets;
dtd, doublet of triplet of doublets; appt, apparent triplet. The 1H-NMR data is presented as follows:
chemical shift in ppm (multiplicity, coupling constant, integration as number of protons). IR spectra
were recorded using a Perkin Elmer Spectrum 400 FT-IR/FT-NIR spectrometer with an attenuated
total reflectance (ATR) attachment. Mass spectra were recorded by Perkin Elmer MS with a Flexar
SQ 300 MS detector using direct infusion electrospray ionization mass spectrometry. Melting points
were measured using the glass capillary method. The melting points were determined using a Stuart
SMP-10 melting point apparatus. All of the melting points were uncorrected.
The physical characteristics of the compounds are reported as physical state, color, and melting
point (m.p.).
3.1.2. General Procedure for the Synthesis of Amino Alcohol Derivatives (2,3)
Pentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-11-dione 1 (5 g, 28.7 mmol) was dissolved in dry
tetrahydrofuran (50 mL) in a 250-mL round-bottom flask. The round-bottom flask was kept in
an external ice bath with stirring, so as to maintain the temperature below 3 ◦C. Amino alcohol
(28.7 mmol) was added drop-wise using a dropping funnel, while stirring at a lower temperature.
The carbinolamine started to precipitate within 10 min, and the mixture was stirred for another 20 min,
after which dry methanol (30 mL) was added, and the mixture was removed from the ice bath. Once all
of the carbinolamine precipitate was dissolved, sodium borohydride (1.5 g) was added slowly, and the
mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo,
water was added, and it was followed by extraction with dichloromethane (4 × 50 mL). Anhydrous
sodium sulphate was used to dry the combined organic fractions, which on evaporation gave a yellow
oil. The mixture was purified using column chromatography (10% ethanol in ethyl acetate).
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8-(2-Aminoethanol)-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (2). A thick transparent liquid, yield:
57.94%. FT-IR (ATR): νmax (cm−1) = 3312.65, 2958.19, 2862.28, 1662.76, 1455.82. 1H-NMR (200 MHz,
CDCl3): δ 4.62 (t, J = 5.2 Hz, 1H), 3.60–3.56 (m, 2H), 3.02–2.98 (m, 2H), 2.85–2.65 (m, 4H), 2.61–2.40
(m, 4H), 1.72 (ABq, J = 10.6 Hz, 2H). 13C-NMR (75 MHz, CDCl3): δ 97.5, 82.39, 63.60, 55.13, 54.79, 46.51,
44.91, 44.62, 44.32, 43.29, 43.15, 41.92, 41.55. MS (ESI) m/z: 219.99 (M + H+), 221.01, 222.02.
8-(3-Aminopropanol)-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (3). A white waxy solid, yield:
35.22%, m.p.: 59–61 ◦C. FT-IR (ATR): νmax (cm−1) = 3169.13, 2956.34, 2862.65, 1664.21, 1509.79. 1H-NMR
(200 MHz, CDCl3): δ 4.64 (t, J = 5.2 Hz, 1H), 3.79 (t, J = 5.4 Hz, 2H), 3.05–2.98 (m, 2H), 2.88–2.68 (m, 8H),
1.72 (ABq, J = 10.6 Hz, 2H), 1.77–1.66 (m, 2H). 13C-NMR (75 MHz, CDCl3): δ 104.60, 82.72, 63.26, 55.41,
54.86, 44.93, 44.89, 44.66, 44.40, 43.10, 42.96, 41.89, 41.63, 32.34. MS (ESI) m/z: 234.28 (M + H+), 235.22,
236.24.
3.1.3. Procedure for Synthesis of Aza-Bridged Compounds 20
4-Benzyl-4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecan-3-ol (20)
A solution of mono ketal cage 19 (0.7 g, 3.20 mmol) and benzyl amine (0.344 g, 3.21 mmol) in
2.5 mL ethanol was reacted in a microwave reactor (µwave = 150 W, T = 100 ◦C, P = 250 Psi) in a sealed
10-mL microwave vessel. Progress of the reaction was monitored by TLC. After the completion of the
reaction (TLC, 1 h), NaBH4 (0.243 g, 6.42 mmol) was added portion-wise to the cooled solution, and the
mixture was stirred at room temperature for 8 h. The solution was then concentrated in vacuo, water
(10 mL) was added, and the crude reaction mixture was extracted with dichloromethane (3 × 10 mL).
The combined organic extract was washed with brine (10 mL), dried with anhydrous Na2SO4, and the
solvent was evaporated in vacuo. To the reaction mixture obtained after the evaporation of the solvent,
acetone (20 mL) and aq. 4 M HCl (15 mL) were added. The mixture was stirred at room temperature
for 18 h. After stirring, water (150 mL) was added, and the solution was basified to pH 12–13 with
aq. 1 M NaOH, and extracted with dichloromethane (4 × 30 mL). The combined organic extract was
dried with anhydrous Na2SO4 and concentrated to obtain a crude reaction mixture. The final product
was obtained by column chromatography using a mobile phase made of 40% ethanol and 60% ethyl
acetate as a white crystalline solid, yield: 43.71%, m.p.: 160–162 ◦C. FT-IR (ATR): νmax (cm−1) = 3111.11,
3057.35, 2974.44, 2968.25, 2869.19, 2835.05, 1605.29, 1497.46. 1H-NMR (200 MHz, CDCl3): δ 7.28–7.13
(m, 5H), 3.68 (brs, 1H, OH), 3.55 (ABq, J = 14.9 Hz, 2H, NCH2) 3.21 (t, J = 4.9 MHz, 1H), 2.90–2.40
(m, 7H), 2.28 (t, J = 4.6, 1H), 1.52 (ABq, J = 10.4 Hz, 2H). 13C-NMR (75 MHz, CDCl3): δ 139.29, 128.47,
128.32, 126.74, 64.77, 55.05, 51.65, 50.67, 45.49, 44.59, 42.89, 42.28, 41.62, 41.28. HRMS (ESI/TOF) m/z:
[M + H]+ Calcd. for C18H20NO 266.1545; Found 266.1539.
3.1.4. Procedure for Synthesis of Oxa-Bridged Compounds (4–11)
2-(8,11-Oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-amino)ethyl 2-nitrobenzoate (4)
A solution of 8-(2-aminoethanol)-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane 2 (0.92 g,
4.20 mmol) in dry dichloromethane (30 mL) was cooled down to 0 ◦C in an external ice bath.
1-Ethyl-3-(3′-dimethylamino)carbodiimide (0.65 g, 4.20 mmol), 3-nitrobenzoic acid (0.70 g, 4.19 mmol),
and 4-(dimethylamino)-pyridine (0.05 g, 0.41 mmol) were added while stirring in an ice bath.
After 20 min, the reaction was removed from the ice bath and stirred for 72 h at room temperature.
The progress of the reaction was monitored by TLC. After completion of the reaction, a saturated
solution of sodium bicarbonate (30 mL) was added, followed by extraction with dichloromethane
(4 × 20 mL). Anhydrous sodium sulphate was added to the combined organic fractions to remove
traces of water after extraction. The solvent was evaporated under reduced pressure to give the
crude reaction mixture. The final product was purified from the crude reaction mixture by column
chromatography using a mobile phase made of different proportions of ethyl acetate in hexane as
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a brownish yellow and transparent thick liquid, yield: 38.86%. FT-IR (ATR): νmax (cm−1) = 3329.55,
2964.04, 2864.74, 1729.94, 1649.84. 1H-NMR (200 MHz, CDCl3): δ 7.92–7.89 (m, 1H), 7.77–7.61 (m,
3H), 4.64 (t, J = 5.6 Hz, 1H), 4.44 (t, J = 5.8 Hz, 2H), 3.14 (t, J = 5.8 Hz, 2H), 2.83–2.38 (m, 8H),
1.71 (ABq, J = 10.6 Hz, 2H). 13C-NMR (101 MHz, CDCl3) and DEPT-135: δ 165.35 (C=O), 148.20 (ArC),
132.90 (ArCH), 131.80 (ArCH), 130.05 (ArCH), 127.57 (ArC), 123.84 (ArCH), 110.91 (C-8), 82.39 (C-11),
66.95 (CH2O), 55.19 (CH), 54.74 (CH), 44.82 (CH), 44.53 (CH), 44.50 (CH), 43.22 (CH2NH), 43.10 (CH),
42.27 (CH2), 41.89 (CH), 41.50 (CH). HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C20H21N2O5 369.1450;
Found 369.1448.
The synthesis of compounds (5, 6, and 11) was carried out using amino alcohol derivative 2,
whereas that of compounds (7–10) was done using the amino alcohol derivative 3, and following the
similar procedure as described for compound 4.
2-(8,11-Oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-amino)ethyl 3-nitrobenzoate (5). A brownish yellow
thick liquid, yield: 48.67%. FT-IR (ATR): νmax (cm−1) = 2964.90, 2864.01, 1722.14, 1616.68, 1531.00.
1H-NMR (200 MHz, CDCl3): δ 8.86 (t, J = 1.8 Hz 1H), 8.45–8.34 (m, 2H), 7.65 (t, J = 8 Hz, 1H), 4.64 (t,
J = 5.6 Hz, 1H), 4.46 (t, J = 5.6 Hz, 2H), 3.22 (t, J = 5.8 Hz, 2H), 2.85–2.42 (m, 8H), 1.72 (ABq, J = 10.6
Hz, 2H). 13C-NMR (101 MHz, CDCl3) and DEPT-135: δ 164.52 (C=O), 148.26 (ArC), 135.36 (ArCH),
131.98 (ArC), 129.64 (ArCH), 127.43 (ArCH), 124.63 (ArCH), 110.01 (C-8), 82.53 (C-11), 66.50 (CH2O),
55.31 (CH), 54.76 (CH), 44.85 (CH), 44.68 (CH), 44.57 (CH), 43.29 (CH2NH), 43.10 (CH), 42.52 (CH2),
41.89 (CH), 41.54 (CH). HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C20H21N2O5 369.1450; Found
369.1443.
2-(8,11-Oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-amino)ethyl 4-nitrobenzoate (6). A light yellow solid,
yield: 41.67%, m.p.: 107–109 ◦C. FT-IR (ATR): νmax (cm−1) = 3314.22, 2968.31, 2866.05, 1714.36, 1610.57,
1527.62. 1H-NMR (200 MHz, CDCl3): δ 8.27 (dd, J = 7.0 Hz, 1.8 Hz, 4H), 4.63 (t, J = 5 Hz, 1H),
4.46 (t, J = 5.6 Hz, 2H), 3.21 (t, J = 5.6, 2H), 2.87–2.43 (m, 8H), 1.72 (ABq, J = 10.6 Hz, 2H). 13C-NMR
(75 MHz, CDCl3): δ 164.76, 150.64, 135.70, 130.84, 123.61, 109.35, 82.71, 66.65, 55.51, 54.86, 44.95, 44.82,
44.66, 43.41, 43.17, 42.56, 42.02, 41.64. HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C20H21N2O5
369.1450; Found 369.1443.
3-(8,11-Oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-amino)propyl 2-nitrobenzoate (7). A brownish yellow
and transparent thick liquid, yield 30.67%. FT-IR (ATR): νmax (cm−1) = 3329.05, 2963.70, 2863.58,
1729.28, 1608.97, 1578.27. 1H-NMR (400 MHz, CDCl3): δ 7.90 (dd, J = 7.8, 1.4 Hz, 1H), 7.75 (dd, J = 7.4,
1.8 Hz, 1H), 7.65 (dtd, J = 18.2, 7.6, 1.6 Hz, 2H), 4.61 (t, J = 5.2 Hz, 1H), 4.42 (t, J = 6.4 Hz, 2H), 2.91
(td, J = 7, 2.8 Hz, 2H), 2.83–2.40 (m, 8H), 1.90 (quin, J = 6.8 Hz, 2H) 1.71 (ABq, J = 10.8 Hz, 2H).
13C-NMR (101 MHz, CDCl3) and DEPT-135: δ 165.42 (C=O), 148.29 (ArC), 132.83 (ArCH), 131.72
(ArCH), 129.94 (ArCH), 127.70 (ArC), 123.84 (ArCH), 110.25 (C-8), 82.40 (C-11), 64.68 (CH2O), 55.14
(CH), 54.72 (CH), 44.83 (CH), 44.64 (CH), 44.50 (CH), 43.26 (CH2NH), 43.08 (CH), 41.88 (CH), 41.53
(CH), 40.29 (CH2), 29.88 (CH2). HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C21H23N2O5 383.1607;
Found 383.1599.
3-(8,11-Oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-amino)propyl 3-nitrobenzoate (8). A brownish yellow
and transparent thick liquid, yield: 48.35%. FT-IR (ATR): νmax (cm−1) = 2963.42, 2863.86, 1722.58,
1616.52, 1531.37. 1H-NMR (400 MHz, CDCl3): δ 8.85 (s, 1H), 8.42 (d, J = 9.6 Hz, 1H), 8.36 (d,
J = 8 Hz, 1H), 7.66 (t, J = 8Hz, 1H), 4.62 (t, J = 5.2 Hz, 1H), 4.48 (t, J = 6.4 Hz, 2H), 2.99 (td,
J = 7 Hz, J = 3.2 Hz, 2H), 2.84–2.41 (m, 8H), 1.99 (quin, J = 6.8 Hz, 2H) 1.72 (ABq, J = 10.8 Hz, 2H).
13C-NMR (101 MHz, CDCl3) and DEPT-135: δ 164.50 (C=O), 148.27 (ArC), 135.30 (ArCH), 132.10
(ArC), 129.64 (ArCH), 127.37 (ArCH), 124.54 (ArCH), 110.67 (C-8), 82.40 (C-11), 64.14 (CH2O), 55.19
(CH), 54.75 (CH),44.83 (CH), 44.60 (CH), 44.53 (CH), 43.25 (CH2NH), 43.10 (CH), 41.87 (CH), 41.54
(CH), 40.48 (CH2), 30.14 (CH2). HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C21H23N2O5 383.1607;
Found 383.1604.
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3-(8,11-Oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-amino)propyl 4-nitrobenzoate (9). A creamy white
waxy solid, yield: 40.96%, m.p.: 70–75 ◦C. FT-IR (ATR): νmax (cm−1) = 3308.75, 2964.14, 2850.24, 1709.53,
1603.35, 1519.04. 1H-NMR (400 MHz, CDCl3): δ 8.27 (d, J = 8.8 Hz, 2H), 8.20 (d, J = 8.8 Hz, 2H), 4.63
(t, J = 5.2 Hz, 1H), 4.46 (t, J = 6.4 Hz, 2H), 2.98 (td, J = 7, 3.6 Hz, 2H), 2.84–2.70 (m, 3H), 2.6 (q, J = 6.8
Hz, 2H), 2.53–2.49 (m, 3H), 2.42 (t, J = 4.8 Hz, 1NH), 1.98 (quin, J = 6.7 Hz, 2H) 1.71 (ABq, J = 10.8 Hz,
2H). 13C-NMR (101 MHz, CDCl3) and DEPT-135: δ 164.71 (C=O), 150.51 (ArC), 135.72 (ArC), 130.70
(ArCH), 123.54 (ArCH), 109.99 (C-8), 82.48 (C-11), 64.16 (CH2O), 55.27 (CH), 54.75 (CH), 44.84 (CH),
44.64 (CH), 44.53 (CH), 43.28 (CH2NH), 43.07 (CH), 41.89 (CH), 41.54 (CH), 40.45 (CH2), 30.13 (CH2).
HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C21H23N2O5 383.1607; Found 383.1600.
3-(8,11-Oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-amino)propyl benzoate (10). A colorless and
transparent thick liquid, yield: 30%. FT-IR (ATR): νmax (cm−1) = 3329.96, 2963.35, 2863.19, 1715.27,
1601.74, 1584.17. 1H-NMR (400 MHz, CDCl3): δ 8.03 (d, J = 7.2 Hz, 2H), 7.55 (t, J = 7.6 Hz, 1H), 7.43 (t,
J = 7.6 Hz, 2H), 4.62 (t, J = 5.2 Hz, 1H), 4.41 (t, J = 6.4 Hz, 2H), 2.98 (td, J = 7, 3.6 Hz, 2H), 2.83–2.47 (m,
7H), 2.41 (t, J = 4.8 Hz, 1H), 1.96 (quin, J = 6.6 Hz, 2H) 1.71 (ABq, J = 10.8 Hz, 2H). 13C-NMR (101 MHz,
CDCl3) and DEPT-135: δ 166.62 (C=O), 132.86 (ArCH), 130.34 (ArC), 129.56 (ArCH), 128.32 (ArCH),
109.70 (C-8), 82.47 (C-11), 63.17 (CH2O), 55.26 (CH), 54.72 (CH), 44.83 (CH), 44.68 (CH), 44.51 (CH),
43.29 (CH2NH), 43.06 (CH), 41.90 (CH), 41.54 (CH), 40.53 (CH2), 30.29 (CH2). HRMS (ESI/TOF) m/z:
[M + H]+ Calcd. for C21H24NO3 338.1756; Found 338.1752.
2-(8,11-Oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-amino)ethyl benzoate (11). An off-white crystalline
solid, yield 36.52%, m.p.: 63–65 ◦C. FT-IR (ATR): νmax (cm−1) = 3315.66, 2949.23, 2868.14, 1709.85,
1602.93, 1584.49. 1H-NMR (600 MHz, CDCl3): δ 8.04 (d, J = 7.2 Hz, 2H), 7.55 (t, J = 7.8 Hz, 1H), 7.43
(t, J = 7.8 Hz, 2H), 4.64 (t, J = 5.4 Hz, 1H), 4.42 (t, J = 6 Hz, 2H), 3.23–3.16 (m, 2H), 2.84–2.77 (m, 2H),
2.72 (q, J = 6.6 Hz, 1H), 2.60 (q, J = 6.6 Hz, 1H), 2.56–2.52 (m, 2H), 2.50 (t, J = 4.8 Hz, 1H), 2.42 (t,
J = 4.8 Hz, 1H), 1.72 (ABq, J = 10.8 Hz, 2H). 13C-NMR (101 MHz, CDCl3) and DEPT-135: δ 166.55
(C=O), 132.92 (ArCH), 130.23 (ArC) 129.63 (ArCH), 128.33 (ArCH), 109.32 (C-8), 82.58 (C-11), 65.64
(CH2O), 55.39 (CH), 54.77 (CH), 44.86 (CH), 44.75 (CH), 44.56 (CH), 43.32 (CH2NH), 43.08 (CH), 42.59
(CH2), 41.94 (CH), 41.55 (CH). HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C20H22NO3 324.1600;
Found 324.1598.
3.1.5. Procedure for Synthesis of 8-Benzylamino-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane
(NGP 1-01) (12)
The pentacyclo[5.4.1.02,6.03,10.05,9]undecane-8-11-dione (5 g, 28.74 mmol) was dissolved in dry
tetrahydrofuran (50 mL) taken in a 250-mL round-bottom flask. The round-bottom flask was kept in an
external ice bath with stirring, so as to maintain the temperature at 0 ◦C. Benzyl amine (3.08 g,
28.74 mmol) was added drop-wise using a dropping funnel, while stirring at low temperature.
The carbinolamine started to precipitate in 10 min, and the mixture was stirred for another 20 min, after
which dry methanol (30 mL) was added, and the mixture was removed from the ice bath. Once the
precipitate dissolved, sodium borohydride (1.5 g) was added slowly, and the mixture was stirred
at room temperature overnight. The solvent was evaporated under vacuum, and water was added,
followed by extraction with dichloromethane (4× 50 mL). Anhydrous sodium sulphate was used to dry
the combined organic fractions, which on evaporation gave a brownish reaction mixture. The mixture
was purified using column chromatography (30% ethyl acetate in hexane), and a pure product was
obtained by crystallization from ethyl acetate as white needle-shaped crystals (3.31 g, 12.47 mmol).
The physical and spectral data corresponded to that described in the literature [30,31]. A white
needle-shaped crystalline solid, yield: 43.44%, m.p.: 85–86 ◦C. FT-IR (ATR): νmax (cm−1) = 3331.55,
3306.15, 2969.82, 2940.67, 2860.54, 1485.70, 1451.27. 1H-NMR (400 MHz, CDCl3): δ 7.37 (d, J = 6.8 Hz,
2H), 7.31 (t, J = 7.4 Hz, 2H), 7.23 (t, J = 7.0 Hz, 2H), 4.67 (t, J = 5.4 Hz, 1H), 4.00 (ABq, J = 13.2 Hz, 2H),
2.87–2.79 (m, 2H), 2.73 (appt, J = 6.4 Hz, 1H), 2.63–2.53 (m, 4H), 2.43 (t, J = 4.8 Hz, 1H), 2.21 (brs, 1H,
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NH), 1.73 (ABq, J = 10.4 Hz, 2H). 13C-NMR (101 MHz, CDCl3): δ 140.83 (ArC), 128.39 (ArCH), 127.92
(ArCH), 126.97 (ArCH), 109.62 (C-8), 82.53 (C-11), 55.26, 54.80, 47.83 (CH2NH), 44.89, 44.59, 43.30,
43.17, 42.03, 41.57. HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C18H20NO 266.1545; Found 266.1540.
3.1.6. Procedure for Synthesis of Oxa-Bridged Monoamine Cage 13 and Aza-Bridged Monoamine
Cage 21
8-Amino-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (13)
A solution of NGP1-01, 12 (1 g, 3.77 mmol) in ethanol (10 mL) was placed in a pressure reactor
along with a stirring bar. The pressure reactor was purged with nitrogen as an inert gas. To this
solution was added 0.188 g (calculated as 50 mg per mmol of substrate) of 10% Pd/C. Special care was
taken to make sure that the Pd/C was added in small amounts while opening the pressure reactor for
as little time as possible, considering the pyrophoric nature of dry Pd/C. After the addition of Pd/C,
the pressure tube was sealed properly, and attached to the hydrogen supply. Hydrogen was flushed
through the sealed pressure reactor six times before filling it with hydrogen gas at 206 kPa pressure.
The mixture was stirred for 14 h, while maintaining the internal temperature of the reaction at 50 ◦C.
Completion of the reaction was confirmed by TLC. On completion of the reaction, the reaction mixture
was filtered under vacuum through a sintered glass funnel. Residual Pd/C waste was transferred
to a labeled container that contained water. The filtrate was concentrated, and 10 mL of saturated
NaHCO3 was added. The resulting reaction mixture was extracted with (3 × 7 mL) dichloromethane.
Anhydrous sodium sulphate was added to the organic fractions, and it was filtered to get a clear
organic layer. The dichloromethane was evaporated under reduced pressure to get a white reaction
mixture. A pure mono amine cage product (0.33 g, 1.88 mmol, 49.86%) was obtained by column
chromatography using pure ethyl acetate and 10% ethanol in ethyl acetate as mobile phase. A white
solid, yield: 49.86%, m.p.: 166–168 ◦C. FT-IR (ATR): νmax (cm−1) = 3387.20, 3314.41, 2964.62, 2860.92,
1623.26, 1451.59, 1371.64. 1H-NMR (200 MHz, CDCl3): δ 4.43 (t, J = 5.2 Hz, 1H), 2.70–2.08 (m, 8H),
1.53 (ABq, J = 10.6 Hz, 2H). 13C-NMR (75 MHz, CDCl3): δ 106.31, 83.05, 57.49, 55.16, 47.00, 44.90, 43.40,
42.44, 41.46. MS (ESI) m/z: 176.24 (M + H+), 177.20, 198.24, 199.23, 214.20, 236.16, 373.30.
4-Azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecan-3-ol (21)
The synthesis of compound 21 was carried out from compound 20 by the same procedure as that
for the synthesis of compound 13, except that the hydrogen gas pressure was maintained at 345 kPa.
The spectroscopic data correlated with the literature [18].
A white solid, m.p.: 183–186 ◦C. FT-IR (ATR): νmax (cm−1) = 3237.59, 3065.07, 2951.94, 2865.35,
1456.71, 1351.95, 1320.89. 1H-NMR (400 MHz, CDCl3): δ 3.56 (t, J = 5.0 Hz, 1H), 2.85–2.80 (m,
1H), 2.78–2.70 (m, 2H), 2.65–2.61 (m, 2H), 2.50–2.42 (m, 3H), 1.67 (ABq, J = 10.4 Hz, 2H). 13C-NMR
(101 MHz, CDCl3): δ 60.89 (d), 55.49 (d), 54.46, 46.13 (d), 45.00, 43.52 (d), 42.56, 42.02 (d). MS (ESI) m/z:
176.02 (M + H+), 177.04.
3.1.7. Procedure for Synthesis of Compounds (14–18) and (22)
8-(2-Nitrobenzylamino)-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (14)
Monoamine cage, 8-Amino-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane 13 (0.7 g, 3.99 mmol)
was dissolved in 40 mL of dry acetonitrile in a round-bottom flask. Potassium carbonate (0.828 g,
5.99 mmol) and tetrabutylammonium hydrogensulfate (0.08 g, 0.24 mmol) were added as the base
and phase transfer catalyst, respectively, to the solution in the round-bottom flask, and stirred for
10 min. A drying tube filled with indicator silica was fitted on the neck of the round-bottom flask to
prevent the atmospheric moisture from entering the contents of the round-bottom flask. 2-Nitrobenzyl
bromide (0.863 g, 3.99 mmol) was added to the stirring suspension, and it was heated on a hot plate
that maintained the internal temperature of the reaction mixture at 70 ◦C. A drying tube was fitted on
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the top end of a condenser that was attached to the neck of the round-bottom flask throughout the
reaction. Progress of the reaction was monitored by TLC. After the completion of the reaction (20 h),
the K2CO3 was filtered off using a sintered glass funnel, and washed with acetonitrile. The filtrate and
washings were combined, the solvent was distilled off at reduced pressure, and the crude reaction
mixture was column chromatographed on silica using 10% to 30% ethyl acetate in hexane as mobile
phase to get a thick liquid as the final product, which solidified to a crystalline yellow solid (0.904 g,
2.91 mmol) on long standing. A yellow solid, yield: 72.96%, m.p.: 89–91 ◦C. FT-IR (ATR): νmax (cm−1)
= 3305.90, 2954.93, 2869.17, 1731.88, 1610.49, 1578.06, 1520.84. 1H-NMR (400 MHz, CDCl3): δ 7.92 (dd,
J = 8 Hz, 0.8 Hz, 1H), 7.67 (d, J = 7.2 Hz, 1H), 7.57 (td, J = 7.6 Hz, 1.06 Hz, 1H), 7.39 (td, J = 8 Hz, 1.0 Hz,
1H), 4.64 (t, J = 5.2 Hz, 1H), 4.28 (ABq, J = 15.2 Hz, 2H), 2.85–2.70 (m, 3H), 2.62–2.57 (m, 1H), 2.50–2.48
(m, 3H), 2.42 (t, J = 4.8 Hz, 1H), 1.72 (ABq, J = 10.4 Hz, 2H). 13C-NMR (101 MHz, CDCl3) and DEPT-135:
δ 149.06 (ArC), 136.53 (ArC), 133.02 (ArCH), 130.85 (ArCH), 127.80 (ArCH), 124.61 (ArCH), 109.43
(C-8), 82.61 (C-11), 55.16 (CH), 54.69 (CH), 45.05 (CH2NH), 45.04 (CH), 44.87 (CH), 44.52 (CH), 43.32
(CH2), 43.16 (CH), 41.92 (CH), 41.54 (CH). HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C18H19N2O3
311.1396; Found 311.1394.
Compound 13 was reacted with the appropriate nitro benzyl bromide for the synthesis of
compounds 15 and 16, and with m-nitrophenethyl bromide for compound 17 using the same procedure
as used for compound 14. Compound 22 was also synthesized using the similar procedure, but by
reacting compound 21 with p-nitrobenzyl bromide.
8-(3-Nitrobenzylamino)-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (15). A light yellow crystalline
solid, yield: 79.42%, m.p.: 121–123 ◦C. FT-IR (ATR): νmax (cm−1) = 3321.22, 2967.17, 2860.76, 1582.33,
1521.33, 1441.85. 1H-NMR (600 MHz, CDCl3): δ 8.28 (s, 1H), 8.09 (dd, J = 7.8 Hz, 1.5 Hz, 1H), 7.68 (d,
J = 7.8 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 4.67 (t, J = 5.1 Hz, 1H), 4.11 (ABq, J = 15 Hz, 2H), 2.86–2.83 (m,
1H), 2.82–2.78 (m, 1H), 2.77–2.74 (m, 1H), 2.64–2.60 (m, 1H), 2.56 (t, J = 4.8 Hz, 1H), 2.53–2.50 (m, 2H),
2.44 (t, J = 4.8 Hz, 1H), 2.35 (brs, 1H, NH), 1.73 (ABq, J = 10.2 Hz, 2H). 13C-NMR (101 MHz, CDCl3)
and DEPT-135: δ 148.46 (ArC), 143.51 (ArC), 133.77 (ArCH), 129.17 (ArCH), 122.54 (ArCH), 121.91
(ArCH), 109.42 (C-8), 82.63 (C-11), 55.37 (CH), 54.81 (CH), 46.94 (CH2NH), 45.00 (CH), 44.89 (CH),
44.63 (CH), 43.34 (CH2), 43.18 (CH), 42.00 (CH), 41.58 (CH). HRMS (ESI/TOF) m/z: [M + H]+ Calcd.
for C18H19N2O3 311.1396; Found 311.1395.
8-(4-Nitrobenzylamino)-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (16). A light yellow solid, yield:
84.34%, m.p.: 144–148 ◦C. FT-IR (ATR): νmax (cm−1) = 3333.26, 2964.21, 2861.80, 1598.72, 1506.38,
1431.06. 1H-NMR (400 MHz, CDCl3): δ 8.19–8.10 (m, 2H), 7.55–7.44 (m, 2H), 4.67 (t, J = 5.2 Hz, 1H),
4.11 (ABq, J = 15.2 Hz, 2H), 2.87–2.72 (m, 3H), 2.64–2.60 (m, 1H), 2.53–2.48 (m, 3H), 2.44 (t, J = 4.8
Hz, 1H), 2.36 (brs, 1H, NH), 1.73 (ABq, J = 10.8 Hz, 2H). 13C-NMR (101 MHz, CDCl3) and DEPT-135:
δ 149.06 (ArC), 146.95 (ArC), 128.23 (ArCH), 123.59 (ArCH), 109.45 (C-8), 82.62 (C-11), 55.38 (CH),
54.79 (CH), 47.14 (CH2NH), 44.96 (CH), 44.87 (CH), 44.62 (CH), 43.32 (CH2), 43.18 (CH), 41.98 (CH),
41.58 (CH). HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C18H19N2O3 311.1396; Found 311.1395.
8-(3-Nitrophenethylamino)-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (17). A thick yellow oil, yield:
11.05%. FT-IR (ATR): νmax (cm−1) = 3319.88, 2963.69, 2863.71, 1732.15, 1523.99, 1478.00. 1H-NMR
(600 MHz, CDCl3): δ 8.11 (s, 1H), 8.07 (dd, J = 8.4 Hz, 1.2 Hz, 1H), 7.56 (d, J = 7.2 Hz, 1H), 7.45 (t,
J = 7.8 Hz, 1H), 4.62 (t, J = 5.1 Hz, 1H), 3.16–3.07 (m, 2H), 2.91 (t, J = 7.2 Hz, 2H), 2.82–2.75 (m, 2H),
2.70 (q, J = 6.6 Hz, 1H), 2.59 (q, J = 6.6 Hz, 1H), 2.50–2.45 (m, 3H), 2.41 (t, J = 4.8 Hz, 1H), 1.71 (ABq,
J = 10.8 Hz, 2H). 13C-NMR (101 MHz, CDCl3): δ 148.38 (ArC), 142.13 (ArC), 135.08 (ArCH), 129.22
(ArCH), 123.72 (ArCH), 121.35 (ArCH), 82.52 (C-11), 62.96 (C-8), 55.42 (CH), 54.75 (CH), 44.84 (CH2NH),
44.63 (CH), 44.58 (CH), 44.53 (CH), 43.31 (CH2), 43.07 (CH), 41.91 (CH), 41.55 (CH), 37.04 (Ar-CH2).
HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C19H21N2O3 325.1552; Found 325.1550.
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4-(4-Nitrobenzyl)-4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecan-3-ol (22). A light yellow solid, yield:
59.53%, m.p.: 165–167 ◦C. FT-IR (ATR): νmax (cm−1) = 2960.45, 2873.53, 1598.38, 1515.06, 1491.83.
1H-NMR (400 MHz, CDCl3): δ 8.18 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H), 3.91 (d, J = 14.8 Hz, 1H,
NCH2), 3.56 (brs, 1H, NCH2), 3.30 (t, J = 4.8Hz, 1H, C-11), 2.95 (q, J = 6.5 Hz, 1H), 2.81–2.74 (m, 2H),
2.67–2.59 (m, 2H), 2.54–2.51 (m, 2H), 2.44 (t, J = 4.8 Hz, 1H), 1.65 (ABq, J = 10.6 Hz, 2H). 13C-NMR (101
MHz, CDCl3): δ 147.31, 146.99, 129.06, 123.60, 65.18, 59.16, 54.96, 51.16, 50.96, 45.59, 44.61, 42.97, 42.31,
41.74, 41.31, 24.23. HRMS (ESI/TOF) m/z: [M + H]+ Calcd. for C18H19N2O3 311.1396; Found 311.1396.
8-Phenethylamino-8,11-oxapentacyclo[5.4.0.02,6.03,10.05,9]undecane (18). The synthesis of compound 18
was carried out by reacting compound 13 with phenethyl bromide using a similar procedure as used
for compounds (14–17) and 27, but using the microwave conditions (Power = 250 W, T = 150 ◦C,
P = 200 Psi). The reaction completed after a total reaction time of 3 h (TLC). A whitish thick liquid,
yield: 15.41%. FT-IR (ATR): νmax (cm−1) = 3322.51, 2962.94, 2862.52, 1732.87, 1603.36, 1496.31, 1453.93.
1H-NMR (400 MHz, CDCl3): δ 7.30–7.17 (m, 5H), 4.62 (t, J = 5.2 Hz, 1H), 3.13–3.02 (m, 2H), 2.81 (t,
J = 7.4 Hz, 2H), 2.74–2.56 (m, 4H), 2.51–2.48 (m, 3H), 2.41 (t, J = 4.8, 1H), 1.71 (ABq, J = 10.4, 2H),
1.25 (brs, 1H, NH). 13C-NMR (101 MHz, CDCl3): δ 139.89 (ArC), 128.75 (ArCH), 128.41 (ArCH),
126.12 (ArCH), 82.45 (C-11), 55.35 (CH), 54.76 (CH), 45.01 (CH2), 44.83 (CH), 44.57 (CH), 44.51 (CH),
43.30 (CH2NH), 43.07 (CH), 41.94 (CH), 41.54 (CH), 37.24 (Ar-CH2). HRMS (ESI/TOF) m/z: [M + H]+
Calcd. for C19H22NO 280.1701; Found 280.1692.
3.1.8. Procedure for Synthesis of 3-Hydroxy-5-cyano-4-benzyl-4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]
Dodecane (23)
The pentacyclo[5.4.1.02,6.03,10.05,9]undecane-8-11-dione (5 g, 28.74 mmol) was dissolved in dry
tetrahydrofuran (50 mL) in a 500-mL round-bottom flask. The round-bottom flask was kept in
an external ice bath with stirring, so as to maintain the temperature below 3 ◦C. Benzylamine (3.08 g,
28.74 mmol) was added drop-wise using a dropping funnel, while stirring at a lower temperature.
The carbinolamine started to precipitate in 10 min, and the mixture was stirred for another 20 min, after
which dry methanol (250 mL) and acetic acid (15 mL) were added, and the mixture was removed from
the ice bath. Once all of the precipitate had dissolved, sodium cyanide (2.11 g, 43.06 mmol) was added
portion-wise, and the reaction mixture was stirred overnight. The reaction mixture was concentrated in
vacuo, and water (100 mL) was added to the concentrated reaction mixture in the round-bottom flask.
Solid NaHCO3 was added to the resulting suspension until the effervescence resulting from carbon
dioxide evolution ceased. Additional solid NaHCO3 was added to the suspension, and it was extracted
with dichloromethane (4 × 50 mL). The combined organic fraction was dried with anhydrous sodium
sulphate, and the dichloromethane was evaporated under reduced pressure. The solid reaction mixture
obtained was crystallized from isopropanol to give a white solid, which was further recrystallized
from dichloromethane to give white long needle-shaped crystals of the product, yield: 39.61%, m.p.:
152–155 ◦C. FT-IR (ATR): νmax (cm−1) = 3093.63, 2957.91, 2871.24, 2237.59, 1606.05, 1496.74, 1454.51,
1371.09, 1331.92. 1H-NMR (200 MHz, CDCl3): δ 7.29–7.13 (m, 5H), 3.67 (s, 2H, NCH2), 3.15–2.40 (m,
7H), 1.96 (brs, 1H, OH), 1.63 (ABq, J = 11.0 Hz, 2H). 13C-NMR (75 MHz, CDCl3): δ 138.70, 128.67,
128.33, 127.26, 119.92, 101.47, 57.18, 53.67, 51.08, 48.07, 45.76, 44.47, 42.50, 42.23, 40.53, 40.18. HRMS
(ESI/TOF) m/z: [M + H]+ Calcd. for C19H19N2O 291.1497; Found 291.1488.
3.2. Biological Studies
3.2.1. Cytotoxicity Studies
PC12 cells were seeded into 96-well microtiter plates at a cell density of 60,000 cells/mL,
using 100 µL of the cell suspension per well (6000 cells/well). The microtiter plates were incubated
for 24 h in a humidified incubator and 5% CO2 at 37 ◦C, prior to addition of the compounds.
The compounds were diluted to double the desired final maximum test concentration with a complete
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medium. Working concentrations were prepared by serial dilutions ranging between 3.125–400 µM.
Aliquots of 100 µL of these different compound dilutions were added to the appropriate microtiter
wells already containing 100 µL of medium, resulting in the required final compound concentrations
(ranging between 1.5265–200 µM). Following test sample addition, plates were incubated for 48 h at
37 ◦C and 5% CO2 in a humidified incubator.
After 48 h, the treatments were removed via aspiration, 100 µL of MTT (0.5 mg/mL) [20] was
dissolved in complete medium and added to each well, and the treatments were incubated for 3 h
at 37 ◦C. After 3 h, MTT was removed via aspiration, 100 µL of DMSO was added to each well to
dissolve the formazan crystals, and the absorbance was read at 540 nm using a BioTek® PowerWave
XS spectrophotometer. Cell viability was determined using four replicate wells for each concentration.
Untreated cells were considered to have 100% cell viability (i.e., the mean optical density (OD) of the
untreated wells = 100% viability). Cell viability in test wells was calculated relative to the untreated
control, and expressed as a percentage.
3.2.2. Neuroprotection Studies
PC12 cells were seeded into 96-well microtiter plates at a cell density of 100,000 cells/mL, using
100 µL of the cell suspension per well (10,000 cells/well). The microtiter plates were incubated
for 24 h in a humidified incubator and 5% CO2 at 37 ◦C, prior to the addition of the compounds.
The compounds were diluted to triple the desired working test concentrations (i.e., 15 µM, 75 µM,
and 150 µM) with complete medium [containing RPMI, 10% foetal bovine serum, 5% horse serum,
and 1% penicillin/streptomycin (Biowest, Nuaille, France)]. Aliquots (50 µL) of the working
concentrations were added to the appropriate microtiter wells, yielding test concentrations of 5 µM,
25 µM, and 50 µM of each compound. N-acetyl-L-cysteine (Sigma) was used as the positive control.
An N-acetyl-L-cysteine stock (500 mM) was prepared in sterile water and filter-sterilized. Aliquots
(50 µL) of the working N-acetyl-L-cysteine concentration (1.5 mM) were added to the appropriate
microtiter wells, yielding a final test concentration of 500 µM. Microtiter plates were incubated for 24 h
in a humidified incubator and 5% CO2 at 37 ◦C, following test sample addition. Paraquat dichloride
(Sigma, St. Louis, MO, USA) was used as a neurotoxin. A paraquat dichloride stock (10 mM) was
prepared in sterile water and sterilized by filtration prior to use. Aliquots (50 µL) of a working
paraquat dichloride solution (1 mM) were added to half of the microtiter plates’ wells, yielding a test
concentration of 250 µM. The addition of 50 µL of complete medium to the remaining wells served as
sample controls representing cell viability in the absence of added neurotoxin, but in the presence of
the test compound. Microtiter plates were further incubated for 24 h in a humidified incubator and 5%
CO2 at 37 ◦C, following neurotoxin addition.
After 20 h of neurotoxin treatment, 20 µL of CellTiter-Blue® Reagent (Promega, Madison, MO,
USA) was added to each well, and it was incubated for a further 4 h in a humidified incubator and 5%
CO2 at 37 ◦C. Fluorescence was measured using a BioTek SYNERGY Mx fluorometer (Winooski, VT,
USA) at excitation and emission wavelengths of 560 nm and 590 nm, respectively. The cell viability was
determined using three replicate wells for each treatment, and percentage protection was calculated as
the difference between paraquat-containing and paraquat-free wells.
3.2.3. NMDA-Mediated and Voltage-Gated Ca2+ Influx Studies
The study protocol was approved by the institutional ethical committee (ethics approval
number: SRIRC2012/06/13) for research, and university guidelines were followed throughout the
experiments. Adult Wistar rats (250–300 g) were used. They were allowed free access to food and
water, and maintained at a 12 h day/night cycle.
Preparation of Synaptoneurosomes
Synaptoneurosomes were prepared by a method validated for synaptosomal preparation [25].
Freshly isolated rat brain was put into 15 mL of ice-cooled incubation buffer (118 mM NaCl, 4.7 mM
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KCl, 0.1 mM CaCl2·2H2O, 20 mM HEPES and 30.9 mM glucose monohydrate) taken in a 50-mL Falcon
tube. Incubation buffer was decanted into the waste, and 15 mL of incubation buffer was added
into the falcon tube holding the brain. The incubation buffer was again decanted to get the clear
brain. Then, 20 mL of ice-cooled incubation buffer was transferred to the Falcon tube with the brain.
The contents of the Falcon tube were transferred into the glass homogenizer. The brain tissue was
homogenized by eight strokes of 3 s each. The tissue suspension was transferred into two 15-mL
Falcon tubes, so that each one had approximately 10 mL of the tissue suspension. The tubes were
then centrifuged at 1100× g for 5 min at 4 ◦C. After the centrifugation, the supernatant of both of
the tubes was transferred to another 50-mL Falcon tube, and kept in an ice-box. This supernatant
was then divided as 2-mL aliquots in pre-weighed 2-mL Eppendorf microfuge tubes. The microfuge
tubes were centrifuged at 15,000× g for 20 min at 4 ◦C. The supernatant in these tubes was discarded,
and the tubes were again weighed to find the weight of the synaptoneurosomes/protein pellet in
each Eppendorf tube. The pellets were further diluted with calcium-free buffer (with the same
composition as the incubation buffer, but without CaCl2·2H2O) to get a protein concentration of
3 mg/mL. The resulting suspensions were vortexed to thoroughly mix the suspension. This suspension
(1990 µL) was added into another 2-mL Eppendorf tube, and allowed to reach room temperature,
followed by a 10-µL addition of 1 mM of solution of Fura-2/AM in DMSO, making sure that all of
the solutions involving Fura-2/AM were protected from light at all times. The solution was gently
vortexed to mix the Fura-2/AM thoroughly, and then incubated at 37 ◦C for 30 min, with shaking
at the rate of 280 rpm. The suspension was again centrifuged at 15,000× g for 5 min to remove the
extra-synaptoneurosomal Fura-2/AM. The supernantant was decanted, and the resulting pellets
were re-suspended in calcium-containing buffer (with the same composition as the incubation
buffer, but 2 mM CaCl2·2H2O). The re-suspended suspension was vortexed to make it uniform.
This solution, which had a synaptoneurosome/protein concentration of 3 mg/mL, was further diluted
with calcium-containing buffer so that the final concentration of the suspension was 0.6 mg/mL. This
suspension was kept in the dark at room temperature for further use in the next step of the experiment.
Measurement of Intracellular Calcium for NMDA-Mediated Studies
Stock solutions of all of the test compounds (10 mM) were prepared by dissolving them in DMSO.
Stock solutions (2 µL) of each of the reference and the test compounds were transferred into individual
wells on a 96-well plate in triplicate. The stock solutions in the wells were further diluted with 200 µL
of synaptoneurosomal-Fura-2/AM solution, so that the final concentration of the reference and the
test compounds in the wells was 100 µM. The well plate was then placed into the fluorescent plate
reader, where incubation was done at 37 ◦C for 30 min, followed by shaking for 10 s before fluorescent
readings. Dual wavelength excitation was done at 340 nm and 380 nm, whereas emission fluorescence
was measured at 510 nm. The fluorescent measurements of each well were done at intervals of 0.5 s for
35 s. Then, 10 µL of stimulation buffer (0.1 mM CaCl2·2H2O, 0.1 mM glycine, and 0.1 mM NMDA)
was introduced in the wells at 10 s after initiation of the experiment by an auto-injector built into the
plate reader to activate NMDAR-mediated calcium influx. The experiments were repeated three times
on different tissue preparations.
Measurement of Intracellular Calcium for Voltage-Gated Studies
The same procedure was followed as for the NMDA-mediated Ca2+ influx studies, except that
the stimulation buffer was replaced by a depolarizing buffer (5.4 mM NaCl, 140 mM KCl, 1.4 mM
CaCl2·2H2O, 20 mM HEPES, 5.5 mM glucose monohydrate, 10 mM NaHCO3, 0.6 mM KH2PO4, 0.6 mM
Na2HPO4.12H2O and 0.9 mM MgSO4).
Calculation of Percentage Inhibition in NMDA and VG-Mediated Ca2+ Influx
The fluorescent data of each cell was expressed as the ratio of fluorescence intensity at 340 nm
and 380 nm. The concentration of free intracellular Ca2+ was proportional to ratio of fluorescence at
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340/380 nm. The average ratio before stimulation was subtracted from the average of the ratio over
25 s after stimulation to get the net Ca2+ influx. This calculation was performed for all of the individual
wells, and the mean was calculated for all of the wells with the same test compound to give a mean
Ca2+ influx as [R]. These [Ca2+] values were used to calculate the percentage inhibition of the test
compounds relative to the control by using the following formula:
% Inhibition =
[R]control − [R]test
[R]control
× 100
R control = Mean Ca2+ influx of control
R test = Mean Ca2+ influx of test compound
3.2.4. S-Nitrosylation Studies
Equimolar quantities of cysteine–glycine and a NO donor were taken in Eppendorf microfuge
tubes. This was achieved by mixing 200 µL of 4 mM Cys–glyc solution, and 80 µL of 10 mM NO-donor
stock solution in 2-mL Eppendorf microfuge tubes. The mixture was stirred at room temperature in
the dark for one hour; then, 200 µL of 20 mM methyl methanethiosulfonate (MMTS) solution was
added to each microfuge tube, which were incubated at 50 ◦C for 20 min with frequent shaking.
To each microfuge tube, 200 µL of acetone was added, and they were vortexed for 10 min. No MMTS
precipitates were formed, contrary to the reported methods. An aliquot of 85 µL was transferred from
each Eppendorf microfuge tube to a separate well in the microplate, and 25 µL of biotin-HPDP (4 mM)
was added to each well in the microplate. The UV absorbance at 343 nm was measured for up to
15 min, with five-minute time intervals. The absorbance of each sample test run was zeroed, with the
absorbance of its reagent blank solution. For a reagent blank sample, the same procedure was used,
but without the addition of the cys–gly dipeptide solution, as this was the only solution in the assay
without any UV absorbance ability. For the control, the same procedure was followed, but without
the addition of NO-donor compounds and MMTS, allowing the cysteine to react completely with the
biotin-HPDP and give an indicative UV absorbance for 100% S-nitrosylation. The absorbance of the
control solution was also adjusted with the absorbance of its own blank solution, which had only HEN
buffer and biotin-HPDP.
4. Conclusions
As is evident from the results obtained in the five different biological studies (Table 3) for the
tested compounds, it was difficult to draw a simple correlation that could explain the results across
all of the biological study domains. The three compounds (8, 4, and 6) with the best neuroprotective
behavior also had a high to medium inhibitory effect on NMDA-mediated and voltage-mediated
calcium influx. However, not all of the compounds with potent channel inhibitory activity showed
good neuroprotection, e.g., compound 15 and 9 had the highest NMDAR-inhibiting activity (94.48%
and 80.29%, respectively) amongst the tested compounds, but displayed a mediocre neuroprotection
behavior (11.21% and 3.42% respectively). This might be because the Ca2+ influx inhibitory studies and
neuroprotection studies were done on two different biological systems, viz. synaptoneurosomes
and PC12 cells, respectively, and evaluated different mechanisms of possible neuroprotection.
The compounds with nitro groups generally showed improved NMDA and voltage-mediated calcium
influx inhibition and neuroprotection, but the extent of S-nitrosylation did not correlate with the
neuroprotective and calcium channel activities.
These results reiterate the fact that neuroprotection is a result of multifactorial biochemical
mechanisms and interactions. As evident from these compounds, the significant inhibition of
calcium flux (NMDA and voltage mediated), and thus possible protection against excitotoxicity,
does not necessarily correlate to the neuroprotection observed in, for example, the paraquat assay,
which is based on oxidative stress and mitochondrial toxicity. Structures exhibiting activity in
diverse neurodegenerative processes and assays could thus be advantageous in terms of multipotent
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neuroprotection. The channel activity and the NMDAR antagonism is also controlled by the
non-covalent interactions between the receptor and the antagonist; this is where the geometric and
steric factors sometimes can dominate the other biochemical factors, as has been suggested in earlier
studies evaluating the calcium channel activity and the NMDAR antagonism of these structures [27,32].
Table 3. Consolidated biological results of the test compounds.
Code %CYT 50 µM %NP 50 µM %NMDA 100 µM %VG 100 µM %S-NO
4 93.68 28.17 * 51.04 30.54 8.14 *
5 84.3 24.48 at 25 µM 57.74 * 37.91 7.81 *
6 98.27 26.55 * 62.17 *** 39.95 * 7.76 *
7 109.14 14.53 at 5 µM 49.26 * 38.51 1.61
8 111.05 39.62 * 71.66 *** 41.18 * 2.09
9 113.29 3.42 80.29 *** 23.61 2.42
10 117.1 9.52 62.92 ** 46.03 * n. d.
11 97.62 14.25 at 5 µM 41.88 30.33 n. d.
12 100.13 19.88 * at 25 µM 50.84 ** 30.71 n. d.
14 90.37 24.87 53.19 * 36.79 0.68
15 109.08 11.21 94.48 **** 29.35 7.89 *
16 93.21 18.71 ** 59.6* 47.15 ** 9.77 **
17 102.91 16.69 50.47 38.91 * 8.34 *
18 92.45 12.72 at 5 µM 55.43 * 49.69 ** n. d.
20 88.05 0.29 24.92 35.69 n. d.
22 130.70 24.92 * 55.22 * 43.76 * 5.40
23 128.73 15.33 * 30.78 26.68 n. d.
CYT = % viability at 50 µM concentration, NP = % neuroprotection of test compounds when tested against
neurotoxin paraquat at 50-µM concentration, unless specified in the table, NMDA = Mean percentage of inhibition
of NMDA-mediated calcium influx when tested with murine synaptoneurosomes at 100-µM concentration of
test compounds, VG = Mean percentage of inhibition of voltage-gated calcium influx when tested with murine
synaptoneurosome at 100-µM concentration of test compounds, S-NO = Percent of S-nitrosylation caused by the test
compounds relative to the control. n.d. stands for not determined. The asterisks indicate the statistical significance
(*, p < 0.05; **, p < 0.005; ***, p < 0.001 and ****, p < 0.0001) when compared to the control.
The absence of any direct correlation between the extent of the nitrosylating ability of these
cage amines and the inhibition of calcium influx is in agreement with a previous report [33].
For the compounds not showing the expected neuroprotection or calcium channel inhibition in
spite of some appreciable S-nitrosylation, the extent of nitrosylation, and hence the modulation of
the calcium channel, might not be sufficient to negate the other factors contributing towards the
inhibition of calcium influx. This hypothesis can be established by attaching NO-donating groups
with higher S-nitrosylating abilities to these compounds, and testing their effect on NMDA and
depolarization-induced calcium influx.
One interpretation of these biological data is that the presence of a nitro group on the phenyl
ring in general enhanced the neuroprotective and calcium channel activities. Apart from affecting
the S-nitrosylation, the nitro group also affects the pi-electron density on the phenyl ring by its
electron withdrawing effect. One suggested hypothesis for the functional antagonism of such cage
compounds was that the phenyl ring undergoes pi–pi interactions with aromatic amino acids located
at the entrance of the NMDA receptor [27]. This helps the molecule become anchored by the phenyl
ring, so that the cage enters through the length of the channel, and interacts at its binding site.
The electron withdrawing effect of the nitro group may provide a favorable electron density for
effective pi–pi interactions. According to a mathematical model based on σ and pi atomic charges,
relative orientations, and van der Waals interactions to determine the electrostatics of the substituent
effect [34], electron withdrawing groups decrease the negative quadropole of the aromatic ring, and
thus favour the parallel displaced and sandwich conformations. This could explain the better calcium
channel inhibitory properties of compounds with nitro groups, by better anchoring of these molecules
at the entrance of the calcium channel.
The above studies reveal important aspects of the structure–activity relationships of
pentacycloundecylamine neuroprotective compounds across different biological study realms.
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The observed neuroprotective, NMDAR, and VGCC channel inhibition and nitrosylating abilities of
NO-donating compounds, combined with the very good cytotoxicity profiles of all of the compounds,
provide a useful contribution to multitarget neuroprotective drug discovery.
The selected approach in the design of the compounds could be translated to designing
compounds with different chemical functionalities and for different therapeutic targets. This has
paved the way for further research, which is not limited to, but may include using better NO donors
on the same/similar molecular scaffolds, incorporating similar aspects of S-nitrosylation for other
therapeutic compounds, and further in vivo studies of these compounds that could shed light on the
functional application of these compounds.
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